Cytokinetics reports positive Phase 3 ACACIA-HCM results; plans FDA sNDA in Q4 2026
Cytokinetics says Phase 3 ACACIA-HCM results are positive and it plans to file an FDA sNDA in Q4 2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.